- Home
- CLEU vs CMND Comparison
CLEU vs CMND Comparison
Compare CLEU & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLEU
- CMND
- Stock Information
- Founded
- CLEU 2011
- CMND 2017
- Country
- CLEU China
- CMND Canada
- Employees
- CLEU N/A
- CMND N/A
- Industry
- CLEU Other Consumer Services
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- CLEU Real Estate
- CMND Health Care
- Exchange
- CLEU Nasdaq
- CMND Nasdaq
- Market Cap
- CLEU 1.0B
- CMND 7.5M
- IPO Year
- CLEU 2020
- CMND N/A
- Fundamental
- Price
- CLEU $3.88
- CMND $1.49
- Analyst Decision
- CLEU
- CMND
- Analyst Count
- CLEU 0
- CMND 0
- Target Price
- CLEU N/A
- CMND N/A
- AVG Volume (30 Days)
- CLEU 277.9K
- CMND 2.9M
- Earning Date
- CLEU 01-14-2025
- CMND 01-15-2025
- Dividend Yield
- CLEU N/A
- CMND N/A
- EPS Growth
- CLEU N/A
- CMND N/A
- EPS
- CLEU N/A
- CMND N/A
- Revenue
- CLEU $2,413,409.00
- CMND N/A
- Revenue This Year
- CLEU N/A
- CMND N/A
- Revenue Next Year
- CLEU N/A
- CMND N/A
- P/E Ratio
- CLEU N/A
- CMND N/A
- Revenue Growth
- CLEU N/A
- CMND N/A
- 52 Week Low
- CLEU $0.12
- CMND $0.92
- 52 Week High
- CLEU $5.00
- CMND $3.58
- Technical
- Relative Strength Index (RSI)
- CLEU 75.94
- CMND 54.92
- Support Level
- CLEU $0.12
- CMND $1.36
- Resistance Level
- CLEU $5.00
- CMND $2.18
- Average True Range (ATR)
- CLEU 0.51
- CMND 0.17
- MACD
- CLEU 0.37
- CMND 0.02
- Stochastic Oscillator
- CLEU 77.04
- CMND 33.65
About CLEU China Liberal Education Holdings Limited
China Liberal Education Holdings Ltd is an educational service provider operating in China. The company's operating segment includes Sino-foreign Jointly Managed Academic Programs, textbooks and course material sales, Overseas Study Consulting Services, Technological Consulting Services for Smart Campus Solutions and Tailored Job Readiness Training Services. Geographically, it derives revenue from China.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.